Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood Test Approved For Viruses Linked To Leukemia

By LabMedica International staff writers
Posted on 11 Apr 2012
A test has been approved that will detect antibodies to viruses in donors of human blood and blood components that are associated with several diseases.

The test can be used to both screen the blood supply for antibodies to Human T-Lymphotropic Virus Type I (HTLV-I) and Human T-Lymphotropic Virus Type II (HTLV-II), and help diagnose infection with these viruses, which are associated with some forms of leukemia and neurologic diseases. More...


The HTLV-I/II Microelisa System is intended for screening living individual human donors, including volunteer donors of whole blood and blood components for the presence of HTLV antibodies. It is also approved for testing serum and plasma specimens to screen potential organ donors when specimens are obtained while the donor’s heart is still beating. It is not intended to be used to screen cord blood specimens or cadaveric blood specimens.

Developed as a standard two-step indirect microelisa system assay, the HTLV-I/II Microelisa System contains coated 96-well microwell plates, color-coded, liquid negative and positive control. Derived from purified and inactivated HTLV-I viral lysate, a purified HTLV-II viral lysate, and a recombinant HTLV-I p21E antigen, the HTLV-I/II Microelisa System is an enzyme-linked immunosorbent assay (ELISA). The HTLV-I/II Microelisa System is manufactured by Avioq Inc., (Research Triangle Park, NC, USA). This Avioq test has received approval from the US Food and Drug Administration (FDA; Silver Spring, MD, USA).

The Avioq HTLV-I/II assay features a user-friendly microplate design suitable for various testing volumes and automation. In addition to being used as a manual assay, the assay is also intended for use with the ORTHO Summit System (Ortho Clinical Diagnostics, Rochester, NY, USA) in the screening of blood donors. Both HTLV-I and HTLV-II can be transmitted through transfusion, reuse of syringes, and by breast-feeding from infected mothers.

Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, said, "Since 2008, there has been only one FDA-licensed donor screening test available for detection of antibodies to HTLV. This approval provides an additional test for HTLV, providing greater flexibility to blood establishments and helping to assure the safety of the blood supply." Screening of all blood donors in the USA for evidence of HTLV infections is required to assure the safety of blood transfusions.

Related Links:

Avioq Inc.
Ortho Clinical Diagnostics
US Food and Drug Administration



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.